CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

Post-LOE

candesartan cilexetil and hydrochlorothiazide

ANI Pharmaceuticals

ANDAORALTABLET

Approved

Nov 2017

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE (candesartan cilexetil and hydrochlorothiazide) by ANI Pharmaceuticals is mechanism of action angiotensin ii is formed from angiotensin i in a reaction catalyzed by angiotensin-converting enzyme (ace, kininase ii). Approved for hypertension, to lower blood pressure, heart failure. First approved in 2017.

Drug data last refreshed 18h ago

Mechanism of Action

Mechanism of Action Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and…

Worked on CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

Mechanism of Action

Indications (3)